Details of the Drug

General Information of Drug (ID: DMDWZGJ)

Drug Name
5-hydroxy-L-tryptophan
Synonyms 5-hydroxytryptophan
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 220.22
Topological Polar Surface Area (xlogp) -1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Metabolism
The drug is metabolized via a vitamin B6 dependent reaction in nervous tissue and in the liver [2]
Chemical Identifiers
Formula
C11H12N2O3
IUPAC Name
(2S)-2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid
Canonical SMILES
C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(=O)O)N
InChI
InChI=1S/C11H12N2O3/c12-9(11(15)16)3-6-5-13-10-2-1-7(14)4-8(6)10/h1-2,4-5,9,13-14H,3,12H2,(H,15,16)/t9-/m0/s1
InChIKey
LDCYZAJDBXYCGN-VIFPVBQESA-N
Cross-matching ID
PubChem CID
439280
ChEBI ID
CHEBI:17780
CAS Number
4350-09-8
DrugBank ID
DB02959
TTD ID
D09BNS
VARIDT ID
DR01071

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 36 member 1 (SLC36A1) TTUYIZW S36A1_HUMAN Inhibitor [3]
Solute carrier family 36 member 2 (SLC36A2) TT5U0XA S36A2_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from 5-hydroxy-L-tryptophan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Methylene blue. Acquired methaemoglobinaemia [3A93] [5]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Oliceridine. Acute pain [MG31] [6]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Levomilnacipran. Chronic pain [MG30] [7]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Vilazodone. Depression [6A70-6A7Z] [7]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Vortioxetine. Depression [6A70-6A7Z] [7]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Milnacipran. Depression [6A70-6A7Z] [8]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Desvenlafaxine. Depression [6A70-6A7Z] [7]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of 5-hydroxy-L-tryptophan and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [9]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Ozanimod. Multiple sclerosis [8A40] [10]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Lorcaserin. Obesity [5B80-5B81] [9]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of 5-hydroxy-L-tryptophan and Safinamide. Parkinsonism [8A00] [5]
⏷ Show the Full List of 11 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4671).
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73.
4 Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70.
5 Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
6 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
7 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
8 Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995): 428-9. [PMID: 8548727]
9 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
10 Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41. [PMID: 12639177]